TARS
NASDAQ
$57.26
Tarsus Pharmaceuticals Inc (TARS)
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $94.56 (+65.14%)
Market Cap
$2.47B
Revenue 5Y CAGR
+74.12%
Free Cash Flow Yield
-1.27%
Beta (5Y)
0.61
Price Chart
Valuation
Market Cap$2.47B
Forward P/E106.38
P/S4.69
P/B7.02
Profitability
Total Revenue (TTM)$535M
Gross Profit (TTM)$428M
EBITDA-$50M
Profit Margin-4.3%
Operating Margin-3.8%
EPS-$1.14
Financial Health
Debt-to-Equity20.8%
Free Cash Flow Yield-1.27%
Growth & Risk
Revenue 5Y CAGR+74.12%
Beta (5Y)0.61
Sharpe Ratio0.81